Arcutis Biotherapeutics

Arcutis boasts positive data for topical Phase III candidate Roflumilast
Arcutis boasts positive data for topical Phase III candidate Roflumilast
Clinical Trials Arena
Arcutis Biotherapeutics
roflumilast
clinical trials
Flag link:
One down, one to go: Arcutis' repurposed AstraZeneca drug clears first PhIII eczema trial
One down, one to go: Arcutis' repurposed AstraZeneca drug clears first PhIII eczema trial
Endpoints
Arcutis Biotherapeutics
eczema
clinical trials
roflumilast
Flag link:
With first drug on the market, Arcutis forks over $16M cash for a buyout
With first drug on the market, Arcutis forks over $16M cash for a buyout
Endpoints
M&A
Arcutis Biotherapeutics
Ducentis BioTherapeutics
Flag link:
With ‘bold experiment’ in drug pricing, Arcutis aims to stand out in plaque psoriasis
With ‘bold experiment’ in drug pricing, Arcutis aims to stand out in plaque psoriasis
MedCity News
Arcutis Biotherapeutics
Zoryve
plaque psoriasis
drug pricing
Flag link:
FDA Action Alert: Incyte, Arcutis Await Decisions in Vitiligo, Psoriasis
FDA Action Alert: Incyte, Arcutis Await Decisions in Vitiligo, Psoriasis
BioSpace
FDA
Incyte
Arcutis Biotherapeutics
Opzelura
vitiligo
roflumilast
psoriasis
Flag link:
Arcutis showcases positive PhIII data showing its topical cream scratched the sweet spot Otezla or steroids couldn't
Arcutis showcases positive PhIII data showing its topical cream scratched the sweet spot Otezla or steroids couldn't
Endpoints
Arcutis Biotherapeutics
clinical trials
ARQ-151
plaque psoriasis
Flag link: